BRIEF-Astrazeneca says U.S. FDA approved BEVESPI aerosphere inhalation aerosol indicated for treatment of patients with chronic obstructive pulmonary disease
April 25, 2016 at 19:46 PM EDT
* US FDA approved BEVESPI aerosphere inhalation aerosol indicated for treatment of patients with chronic obstructive pulmonary disease Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)